Tag: osteogenesis imperfecta (OI)

September 5, 2019 Off

Mereo to present its osteogenesis imperfecta study data in Orlando

Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.

May 4, 2017 Off

Mereo BioPharma starts Phase 2 study of rare bone disease drug

By Dino Mustafić

Mereo BioPharma Group, a clinical stage, biopharmaceutical company focused on rare and specialty diseases, has initiated a potentially pivotal Phase 2b clinical study of BPS-804 for the treatment of the orphan disease, osteogenesis imperfecta (OI) (brittle bone disease), the ASTEROID study.